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 Abstract 
In vitro differentiation of embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) into hematopoietic cells may help to find new strategies 
for the treatment of incurable hematopoiesis disorders and to improve 
(hematopoietic stem cells) HSCs transplantation. In this study we mainly 
focus on the mechanisms of hematopoietic differentiation of ESCs and iPSCs 
at early and late stages, using our knowledge from iPSCs of cyclic 
neutropenia (CyN) and congenital neutropenia (CN) patients. 
We found that TPO and bone morphogenetic protein 4 (BMP4) signaling 
pathway are directly connected. This could elevate early hematopoiesis by 
TPO/c-mpl signaling. TPO-mediated binding of the HIF-1α transcription factor 
to the BMP4 gene promoter mediates early hematopoiesis and activation of 
BMP4 target genes in ESCs.  
We also used an embryoid body (EB)-based protocol of granulocytic 
differentiation of human iPSCs to evaluate the in vitro myeloid differentiation 
of iPSCs derived from one CyN patient harboring a sporadic heterozygous 
ELANE mutation (p.W241L), and one CN patient with an inherited 
familial ELANE mutation (p.C151Y) in comparison with myeloid 
differentiation of iPSCs derived from a healthy donor.  
CyN is a hematologic disorder show cycles at approximately 21-day intervals 
in blood cell counts particularly granulocytic neutrophils, monocytes, 
platelets, and reticulocyte numbers. The majority of CyN patients 
(approximately 90%) show inherited mutations in the ELANE gene and CN 
patients also have inherited ELANE mutations. It is unclear how a mutation 
in the same gene causes CN or CyN. In addition, the pathomechanism of 
cycling in hematopoiesis pathway downstream of ELANE mutations is still 
unclear.  
Using the embryoid body (EB)-based protocol of granulocytic differentiation 
of hiPSCs, we found that the combination of IL-3 with G-CSF is the best 
14 
 
condition to improve our neutrophil maturation protocol for further 
experiments applicable for CN patients derived from iPSCs. We detected 
diminished absolute numbers of CD15+CD16+  that were derived from iPSCs 
of a CyN patient, as compared to that of a healthy individual on day 28 of 
culture. We also found a remarkable reduction of absolute numbers of 
myeloid and granulocytic cells that were generated from iPSCs of a CN 
patient, as compared to cells of healthy individuals on day 28 of culture. 
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1 Introduction 
1.1 Hematopoiesis 
Formation and maturation of blood cells  from hematopoietic stem cells 
(HSCs) is a well-organized process of hematopoiesis (Doulatov, Notta et al. 
2012). Developmental studies of hematopoiesis can help to understand the 
mechanisms of inherited blood cell disorders or blood cancer as well as to 
identify the role of HSCs in aging and oncogenesis (Jagannathan-Bogdan 
and Zon 2013). HSCs are infrequent cells homing in the bone marrow (BM) 
to generate mature blood cell lineages (Orkin and Zon 2008). Using 
monoclonal antibodies against specific surface markers of HSCs they can be 
detected by FACS and separated into committed progenitors (Orkin and Zon 
2008). 
Vertebrate blood cells are developed in a 2-wave program (Fig.1) involving 
the primitive wave and definitive wave. Erythrocytes and macrophages will 
develop in the primitive wave in the early embryonic development (Palis and 
Yoder 2001). in a definitive wave of hematopoiesis, multipotent HSCs will 
form all blood cell lineages (Orkin and Zon 2008). 
It has been demonstrated that all hematopoietic lineages have been derived 
from a common precursor in embryonic stem cells (ESCs) based on 
hemangioblast theory (Kennedy and Eberhart 1997).  
In vertebrates, definitive HSCs will form in the aorta gonad mesonephros 
(AGM) region in the embryo, after that they will migrate to the fetal liver and 
then to the bone marrow (Cumano and Godin 2007).   
Further studies using in vitro differentiation of mouse ESCs proved the theory 
of the existence of hemangioblasts in vertebrates (Choi, Kennedy et al. 
1998). 
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Figure 1. Developmental Regulation of Hematopoiesis in the Mouse  
 a, Hematopoiesis occurs first in the yolk sac (YS) blood islands and later at the aorta-gonad mesonephros 
(AGM) region, placenta, and fetal liver (FL). b, Hematopoiesis in each location and the production of specific 
blood lineages in each region. 
Abbreviations: ECs, endothelial cells; RBCs, red blood cells; LTHSC, long-term hematopoietic stem cell; ST-
HSC, short-term hematopoietic stem cell; CMP, common myeloid progenitor; CLP, common lymphoid progenitor; 
MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitors; c, developmental time 
windows for hematopoiesis (Source from Orkin et al. 2009).  
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1.2 Isolation of HSCs 
In bone marrow, long-term (LT) HSCs generate short-term (ST) HSCs, which 
can produce all blood lineages. Multipotent progenitor cells (MPP) generated 
by ST-HSC can reconstitute all blood components (Doulatov, Notta et al. 
2012, Manz and Boettcher 2014) (Fig.2). These progenitors first form 
common lymphoid progenitors (CLP) that differentiate to B, T, or natural killer 
(NK) cells and common myeloid progenitors (CMP) reconstituting 
megakaryocyte, granulocyte/monocyte and erythrocyte precursors (Fey 
2007, Cotta 2010). Hematopoiesis also depends on the bone marrow niche 
consisting of non-hematopoietic cells, such as fibroblasts, osteoblasts, and 
adipocytes, which are sources of cytokine homing signals for hematopoietic 
cells and mechanical anchorage factors (Fey 2007).  
several specific cell surface markers are required for the purification and 
detection of HSCs. For example, CD34 antigen was the first marker found in 
more than 99 % of hHSCs and in on less than 5 % of all mature blood cells 
(Doulatov, Notta et al. 2012). CD90 was another stem cell marker detected 
by Baum et al. (Baum, Weissman et al. 1992). It was demonstrated that cells 
expressing CD90 (Thy1) in combination with CD34 have the highest multi-
lineage capacity.  More differentiated markers of hematopoietic progenitors 
are CD45RA and CD38 that are negatively enriched in HSCs (Bhatia, Wang 
et al. 1997). Based on these observations, it has been proposed that the 
CD34+CD38–Thy1+CD45RA– cells represent hHSCs. 
HSCs activity is restricted to the CD49f+ cells, CD49f is expressed on 50% of 
human CD90+ and 25% of CD90- cells (Notta, Doulatov et al. 2011).   
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With the application of monoclonal antibodies, cell populations from very 
early hematopoiesis have been separated based on their surface markers, 
and theses population can be sorted with a cocktail of different antibodies. 
However, based on many unknown markers and antibodies, in order to 
Figure 2. Current Models of Lineage Determination in the Adult Human Hematopoietic Hierarchies 
Terminally differentiated cells are shown on the right, and inferred lineage relationships are depicted with 
arrows. In mice (A), HSCs can be separated into long-term (LT), intermediate-term (IT), and short-term (ST) 
classes based on the duration of repopulation. In humans (B), HSCs are defined by the expression of CD49f and 
other markers. In mice, differentiation of HSCs gives rise to transiently engrafting multipotent progenitors (MPPs), 
and a series of immature lymphoid-biased progenitors (such as LMPPs) that undergo gradual lymphoid 
specification. In humans, loss of CD49f expressing cells can be identified as MPPs; Both mice and humans have 
well-defined populations of myelo-erythroid progenitors: CMPs, GMPs, and MEPs. 
Lin: cocktail containing cell surface markers for all terminally differentiated populations (B cell; T cell; NK; dendritic 
cell, monocyte, granulocyte, megakaryocyte, and erythrocyte) (Source from Sergei Doulatov et al.2012).  
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determine if the isolated cell population remains heterogeneous, more 
investigations are required (Lu, Neff et al. 2011). Heterogeneity of stem cells 
plays an important role in cancer, aging or leukemia (Rossi, Jamieson et al. 
2008, Beerman, Bhattacharya et al. 2010). 
 
1.3 Cellular and Molecular Mechanisms in hHSCs Regulation 
GATA1 and PU.1 are two of the most important transcription factors that 
regulate primitive erythroid and myeloid hematopoiesis by cross-inhibition 
(Fig.3). GATA1 is the main regulator of erythrocyte development (Cantor and 
Orkin 2002). By contrast, myeloid cells, which includes macrophages and 
granulocytes mainly will regulate by PU.1. In addition, Runx1 is a member of 
the runt family of transcription factors (RUNX) and that also has a crucial role 
in definitive hematopoiesis (Wang, Mayo et al. 1996). 
There is evidence that osteoblasts are important cells that interact with HSCs 
in the bone marrow and play an essential role in creating a niche for 
hematopoiesis. In addition, vascular cells, as well as vascular niche, are also 
required for HSC regulation (Kiel and Morrison 2006).  
There are some essential signaling pathways and cytokines involved in 
hematopoiesis and formation of hematopoietic progenitors. For example, 
BMP4 is a morphogenic signaling molecule required for the embryonic ventral 
mesoderm formation as well as hematopoietic precursor cells formation 
during embryogenesis (Huber, Zhou et al. 1998, Sadlon, Lewis et al. 2004). 
In Xenopus embryos, transcription factors responsible for hematopoietic-
specification expressions such as GATA-1 and Scl/Tal-1, appear after 
ectopic expression of BMP4 (Maeno, Mead et al. 1996, Zhang and Evans 
1996, Mead, Kelley et al. 1998).  
BMP4 is required for the hematopoietic cells development followed by 
mesoderm induction from pluripotent mouse ESCs (Johansson and Wiles 
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1995, Nakayama, Lee et al. 2000). Mesoderm induction and blood cell 
formation in the yolk sac disrupts following BMP4 mutations. This evidence 
proves the importance role of BMP4 for hematopoietic differentiation 
(Winnier, Blessing et al. 1995).  
BMP signal transduction is elicited through binding of BMP4 to type 1 and 
type 2 serine-threonine kinase receptors (Sadlon, Lewis et al. 2004), deletion 
of one of the BMP receptor molecules (BMPR1A) abolishes mesoderm 
formation (Mishina, Suzuki et al. 1995). Type I receptors are trans-
phosphorylated by constitutive activation of kinase domains of the type II 
receptors (Sadlon, Lewis et al. 2004), this will results in activation of target 
genes, such as Id1, 2, and 3, and Msx1 and 2 (Mishina, Suzuki et al. 1995, 
Sadlon, Lewis et al. 2004, Larsson and Karlsson 2005, Zhang, Li et al. 2008). 
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We have shown that Thrombopoietin (TPO) promotes early hematopoiesis 
from ES cells (Pramono, Zahabi et al. 2016). Mutations in the TPO-receptor, 
c-mpl gene leads to a non-responsiveness of hematopoietic cells to TPO 
which results in the molecular defect of CAMT (congenital amegakaryocytic 
thrombocytopenia) disease (Ihara, Ishii et al. 1999, Fox, Priestley et al. 2002).  
Figure 3. Genes and pathways that control the functions of early progenitors and human HSCs  
Important factors on human HSCs regulation including transcription factors and signaling pathways that play an 
important role for stem cell expansion are shown on the left part of the picture (Source from Sergei Doulatovet 
al.2012). 
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 It has been found that TPO is an important cytokine for the in vivo expansion 
of HSCs (Lok and Foster 1994, Fox, Priestley et al. 2002). TPO also is a 
cytokine with lineage-restriction effects on thrombocytopoiesis and 
megakaryopoiesis (Arai, Takada et al. 1999). However, TPO/c-mpl signaling 
has an essential role in the maintenance of all hematopoietic lineages in 
human (King, Germeshausen et al. 2005).   
 
1.4 Granulocytic Differentiation and Maturation 
Blood cells are divided into two important branches: lymphoid and myeloid. 
T, B, and NK cells are in the lymphoid group that is responsible for adaptive 
and innate immune responses. Granulocytes (neutrophils, basophils 
eosinophils and mast cells), erythrocytes, megakaryocytes and monocytes 
are the fully differentiated and short-lived cells in the myeloid lineage 
(Doulatov, Notta et al. 2012) 
Myeloid progenitors express CD123 (IL-3 receptor) and CD135 (FLT3L) in 
humans (Doulatov, Notta et al. 2012). CMP to GMP transition in myeloid 
progenitors occurs by the acquisition of CD45RA marker. Single 
CD135+CD45RA– CMPs can produce all myeloid lineages, but it cannot 
generate lymphoid, lineages in vitro and in vivo after transplantation into mice 
(Doulatov, Notta et al. 2012). 
Neutrophils are continuously generated from CMPs or GMPs in the BM in 
which a promyelocyte (MB/MP) derived from a myeloblast proliferation into 
myelocyte and fully differentiate into a segmented granule neutrophil (Fig.4) 
(Lekstrom-Himes, Dorman et al. 1999). 
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Transcriptional regulators involved in granulopoiesis are mainly core-binding 
factors (CBFs) and CCAAT/enhancer binding proteins such as C/EBPα 
(Lenny, Westendorf et al. 1997, Ward, Loeb et al. 2000). C/EBPα expression 
decreases with myeloid differentiation reaching a peak in myeloblasts (Scott, 
Civin et al. 1992). Another crucial factor for granulocytic differentiation is the 
lymphoid enhancer-binding factor 1 (LEF-1) transcription factor, which binds 
to and activates C/EBPα (Skokowa, Cario et al. 2006). 
Neutrophils are key mediators of the innate immunity in the defense against 
bacterial and fungal microbes (Zhang, Nguyen-Jackson et al. 2010). They 
ingest and kill invading pathogens and by, releasing inflammatory mediators 
like chemokines, cytokines and oxygen species, they maintain inflammation. 
Thus, in neutrophil deficiency  conditions that lack the number and function 
of PMNs can have important consequences, such as increased capability to 
bacterial infection (Miranda and Johnson 2007). The clinical administration of 
granulocyte-colony stimulating factor (G-CSF or CSF3) can be used to 
enhance or restore the levels of differentiated neutrophils in neutropenic 
patients (Welte, Gabrilove et al. 1996). In addition, administration of G-CSF 
is widely used for the mobilization of HSCs into the peripheral blood, 
facilitating the collection of HSCs for transplantation. 
 
Figure 4. Schema of Granulopoiesis  
Granulopoiesis begins when the myeloblast differentiates into a neutrophilic promyelocyte. The promyelocyte 
can be irreversibly committed to the neutrophilic cell line (Source from Lekstrom-Himes JA et al. 1999). 
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1.5 Role of CSFs in myeloid differentiation 
Colony-stimulating factors (CSF) play an essential role in hematopoietic cell 
proliferation, activation and differentiation (Metcalf 2008). There are 3 
subtypes of CSF: granulocyte colony stimulating factor (G-CSF or CSF3), 
granulocyte–macrophage colony stimulating factor (GM-CSF or CSF2) (Horn 
and Johnson 2010) and macrophage colony-stimulating factor (CSF1 or M-
CSF) (Fig.5). 
There is evidence that deletion of the GM-CSF gene just reduces neutrophil 
function without highly affecting their number, while deletion of genes 
encoding G-CSF, or M-CSF reduces the number of the cells that are 
stimulated by these cytokines (Metcalf 2008).  
G-CSF is involved in both early and late regulation of normal and emergency 
granulopoiesis (Lieschke, Stanley et al. 1994, Skokowa and Welte 2013). 
Moreover, G-CSF has an important effect on hematopoietic progenitor cells 
mobilization from the bone marrow into the peripheral blood, that can be used 
for HSCs transplantation purposes (Molineux, Pojda et al. 1990, Roberts 
2005).  
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1.6 Cyclic Neutropenia (CyN) and congenital Neutropenia (CN) 
disorders 
Heterozygous germline mutations in the ELANE gene which encodes 
neutrophil elastase (NE) (Tidwell, Wechsler et al. 2014) may cause two 
disorders of hematopoiesis: Cyclic neutropenia (CyN) and congenital 
neutropenia (CN). However, it is still not clear how mutations in the same 
gene cause two different diseases. It could be the mislocalization of aberrant 
NE or the disturbed protein folding caused by ELANE mutations inducing an 
unfolded protein response in the endoplasmic reticulum (ER) (Tidwell, 
Wechsler et al. 2014).  
Figure 5. The role of CSFs in myelopoiesis 
a haematopoietic stem cell can form the blood cells under either self-renewal or differentiation into a multilineage 
committed progenitors (common myeloid progenitor). By stimulation of GM–CSF, CMPs can give rise to a further 
differentiated progenitor and can be committed to the granulocytes and macrophages (GM) linage. GM cells can 
give rise to uni-lineage committed progenitors for granulocytes maturation by stimulation with G–CSF, IL-5 and 
SCF or monocytes maturation by stimulation with M–CSF.  
SCF: stem cell factor, TPO: thrombopoietin (Source from Alejandro Francisco-Cruz et al. 2014). 
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CyN is a hematologic disorder in which blood cell counts particularly 
granulocytic neutrophils, monocytes, platelets, and reticulocytes show cycles 
at approximately 21 days intervals (Lange 1983) (Fig.6). 
 
 
 
 
 
 
 
 
 
 
 CN patient’s neutrophil counts are sustained low and their bone marrow 
shows a promyelocytic maturation arrest (Fig.7) (Welte, Zeidler et al. 2006). 
There are also some other gene mutations causing CN, including HAX1, 
GFI1, G6PC3 (Tidwell, Wechsler et al. 2014) and WASP (Wiskott-Aldrich 
syndrome protein) (Skokowa and Welte 2009). Different mutations can lead 
to defects in the same downstream signaling pathways, resulting in the 
maturation arrest of promyelocytes in CN patients (Skokowa, Germeshausen 
et al. 2007, Zeidler, Germeshausen et al. 2009). More than 20% of patients 
will go on to develop acute myelogenous leukemia (AML) therefore, CN is 
considered to be a pre-leukemic syndrome (Rosenberg, Alter et al. 2006).   
 
Figure 6. Course of Neutrophils in a Patient with Cyclic Neutropenia (CyN) (Source from Lange RD 1983). 
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The ELANE mutations causing CN sometimes overlap those seen in CyN 
(Horwitz, Duan et al. 2007) (Fig.8). Heterozygous mutation of ELANE also 
causes almost all cases of CyN  (Horwitz, Benson et al. 1999)  and the 
majority of CN (Dale, Person et al. 2000). Most ELANE mutations are 
dominant heterozygous single nucleotide mutations (Nayak, Trump et al. 
2015). 
 
 
 
 
 
 
Figure 7. Morphological picture of bone marrow (BM) in healthy individual (left) and congenital 
neutropenia (CN) patient (right).  
Granulocytic progenitors and neutrophils are presented in healthy BM (marked with blue arrows) and absent in 
CN patient (Source from Welte, Zeidler et al. 2006). 
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CN patients respond to high doses G-CSF therapy, which increases 
neutrophil blood counts to above 1000/µl and by that prevents life-threatening 
bacterial infections (Dale, Cottle et al. 2003). The risk of leukemia 
development directly correlates with the G-CSF dose required (Rosenberg, 
Alter et al. 2006), and with the variant of CN (Horwitz, Corey et al. 2013). It 
has been discussed, that life-long treatment with G-CSF predisposes CN 
patients to myelodysplastic syndrome (MDS) and acute myeloid leukemia 
(AML) (Freedman and Alter 2002) with a 20% cumulative incidence observed 
after 10 years (Dale, Cottle et al. 2003, Dale, Bolyard et al. 2006). 
 
1.7 Defective signaling pathways in CN  
With the first successful clinical trials of human G-CSF in patients with CN in 
1987 (Bonilla, Gillio et al. 1989, Kimura, Toyama et al. 1995), the clinical 
outlook and quality of life of CN patients was dramatically improved.  
Multimerization of G-CSFR occurs by binding to its ligand followed by 
tyrosine phosphorylation of proteins, and activation of several intracellular 
Figure 8. Cyclic and congenital neutropenia ELANE mutations  
 Mutations of SCN in 307 patients has been shown above the map, and those mutations seen in CyN are below. 
Shared mutations in both SCN and CyN has been represented in bold.  
AML, acute myeloid leukemia; CyN, cyclic neutropenia; MDS, myelodysplasia; SCN, severe congenital 
neutropenia (Source from Makaryan V et al. 2015). 
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signaling pathways, such as JAK/STAT, phosphatidylinositol-3’-kinase 
(PI3)/AKT and Ras/Raf/MAPK (mitogen-activated protein kinase) pathways. 
This results in transcriptional changes that influence proliferation, survival, 
migration, and differentiation (Touw and van de Geijn 2007).  
The canonical Wnt signaling pathway includes the LEF/TCFs (or T-cell 
factors) family of transcription factors that cooperate  with β-catenin to make 
transcriptional complexes on target genes (van de Wetering, de Lau et al. 
2002). It has been shown that LEF-1 may also act independently from ß-
catenin (for example, in the TGF-ß and Notch pathways) (Ross and Kadesch 
2001, Nawshad and Hay 2003). 
It has been shown that LEF-1 mRNA and protein expression was dramatically 
downregulated or absent in promyelocytic cells of the CN patients compared 
to healthy individuals (Fig.9) (Skokowa, Cario et al. 2006). Down-regulated  
LEF-1 expression resulted in decreased LEF-1 target genes, such as cyclin 
D1, survivin, c-Myc and granulopoietic transcription factor C/EBPa.   
It has been shown that C/EBPa is a critical factor in the induction of 
granulocyte differentiation and regulation between proliferation and 
differentiation balance of the myeloid precursors (Zhang, Nelson et al. 2002, 
Ross, Radomska et al. 2004).  
LEF-1 dysfunction in CN patients results in C/EBPa downregulation 
(Skokowa, Cario et al. 2006). In patients with AML disease mutations in 
C/EBPa gene results in the production of non-functional C/EBPa and 
disrupted granulocyte differentiation (Skokowa, Cario et al. 2006).   
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1.8 G-CSF activates NAMPT in CN 
Recently, a new Nicotinamide phosphoribosyltransferase (Nampt) 
/NAD+/SIRT1-dependent activation of protein deacetylation during G-CSF–
triggered myelopoiesis was identified by our group (Skokowa, Lan et al. 
2009). NAMPT is an important activator of NAD+-dependent sirtuin protein 
deacetylases that could convert nicotinamide to nicotinamide 
mononucleotide (Skokowa, Lan et al. 2009). Finally, nicotinamide 
mononucleotide converts into nicotinamide adenine dinucleotide (NAD+) 
(Rongvaux, Shea et al. 2002).  
Upon activation of neutrophils and monocytes by IL-6 and TNF-α, NAMPT is 
up-regulated (Jia, Li et al. 2004, Iqbal and Zaidi 2006, Nowell, Richards et al. 
2006). The NAD+-dependent SIRT1 activation resulted in the activation of 
transcription factors such as C/EBPα and C/EBPβ, which are important in 
granulopoiesis, and subsequent up-regulation of G-CSF synthesis and G-
Figure 9. Myelopoietic maturation through the regulation of specific target genes by LEF-1 transcription 
factor (Source from Skokowa J. et al. 2006). 
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CSFR expression. G-CSF, in turn, enhances NAMPT levels, providing an 
autoregulatory feedback loop (Fig.10) (Skokowa, Lan et al. 2009). In patients 
with CN, disfunction C/EBP-α and thus abrogated steady-state 
granulopoiesis leads to C/EBP-β response in emergency granulopoiesis 
regulation (Fig.9). To activate C/EBPß, high levels of NAMPT and therefore 
daily treatment with high dose of G-CSF is required in CN patients (Skokowa, 
Lan et al. 2009). 
In vitro inhibition of NAMPT could increase apoptosis and cell death in CLL 
cells (Gehrke, Bouchard et al. 2014). NAMPT is over-expressed in patients 
with AML and inhibition of NAMPT leads to apoptosis and cell death of AML 
blasts (Skokowa, Lan et al. 2009, Thakur, Dittrich et al. 2013). Importantly, 
specific pharmacological inhibitors of NAMPT have been designed and are 
now in phase II-III clinical trials (Montecucco, Cea et al. 2013, Tan, Young et 
al. 2013, Chini, Guerrico et al. 2014).  
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1.9 Induced pluripotent stem cells (iPSCs) 
Induced Pluripotent Stem Cells (iPSCs) have been generated by 
reprogramming of  adult or mouse embryonic fibroblasts using four defined 
transcription factors Oct3/4, Sox2, Klf4 and c-Myc (Takahashi and Yamanaka 
2006). Oct3/4 (Niwa, Miyazaki et al. 2000) and Sox2 are responsible for 
maintenance of stem cell pluripotency (Avilion, Nicolis et al. 2003). Klf4 is a 
zinc finger motif-containing transcription factor which is associated with the 
self- renewal of stem cells (Li, McClintick et al. 2005) and c-Myc is an 
oncogenic transcription factor, which induces proliferation and cell cycle. 
iPSCs are similar to ESCs and they have the stem cell-like expression profile, 
and the ability to differentiation into three germ layer cells in teratoma 
formation assays (Takahashi and Yamanaka 2006). iPSCs are a wide source 
for cell replacement transplantations, disease modeling, regenerative 
medicine and drug discovery (Wu and Hochedlinger 2011). iPSCs are a 
model to discover the early and late human development and cellular 
differentiation (Fig.11) (Lee, Kim et al. 2014). iPSCs have already been 
Figure 10. Dose-dependent role of NAMPT in healthy individuals and in congenital neutropenia 
 G-CSFR activation induces NAMPT synthesis leading to the increase of NAD+ levels. Activation of NAD+-
dependent SIRT1 results in GCSF and G-CSFR induction of granulopoiesis elevated levels which is C/EBP-α- 
and C/EBP-β-dependent via an outoregulatory loop (left). In patients with CN, the non-functional C/EBP-α leads 
to a defective steady-state granulopoiesis. Thus emergency granulopoiesis controlled by C/EBP-β is activated 
(right). High levels of NAMPT and therefore daily treatment with high doses of G-CSF is required to activate 
C/EBPß in CN patients (Source from Skokowa J. et al. 2009). 
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obtained from patients with various diseases, including disorders of 
hematopoiesis (Giorgetti, Montserrat et al. 2009). 
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Non-integrative reprogramming methods for the safety of translational 
applications are one of the most important issues for reprogramming. For this 
reason, reprogramming using Sendai virus and DNA-based episomal 
reprogramming, mRNA or protein expression reprogramming methods are 
recommended instead of classical lentiviral reprogramming techniques 
(Diecke, Jung et al. 2014). One of the most authentic safe integration-free 
reprogramming is a plasmid-mediated method (Yu, Hu et al. 2009).  
Plasmids containing EBNA1 gene and OriP DNA sequence from Epstein–
Barr virus (EBV) has been one of the most reproducible plasmid systems in 
a safe iPSCs generation (Chou, Mali et al. 2011). These episomal plasmid 
features allow the plasmid to replicate inside the cell as circular DNA 
(episomes) without any integration into the cellular genome as compared to 
regular plasmids. Safety of this method has been shown by whole genome 
sequencing of episome-reprogrammed iPSCs. Owing to the epigenetic 
silencing of foreign vectors, the presence of expressing reprogramming and 
EBNA1 genes of the episomal vectors is usually transient (Yu, Hu et al. 2009, 
Chou, Mali et al. 2011, Cheng, Hansen et al. 2012). 
Figure 11. Overview of the iPSCs Technology 
patient cells can be reprogrammed into iPSCs using small molecules, microRNAs, and combinations of 
reprogramming factors. Differentiated cells derived from iPSCs could be used either in transplantation therapies 
or to model of human diseases (Source from Hockemeyer D. et al. 2016). 
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Genetic defects in iPSCs can be corrected via targeted editing of the iPSCs 
genome based on the CRISPR method (Al-Attar, Westra et al. 2011), TALEN 
and Zinc-finger nucleases (ZFNs) system (Gaj, Gersbach et al. 2013). iPSCs 
can also spontaneously or directly differentiate into different cell types that 
might be suitable for stem cell therapy, disease modeling and for drug 
screening (Fig.12) (Diecke, Jung et al. 2014). 
Recent studies using iPSCs generated from CN patients with ELANE 
mutations demonstrated markedly diminished granulocytic differentiation of 
these cells in vitro (Hiramoto, Ebihara et al. 2013). Interestingly, correction of 
ELANE mutation in iPSCs from a CN patient using CRISPR/Cas9 technology 
restored defective granulopoiesis, suggesting the monogenic origin of the 
ELANE mutation caused congenital neutropenia (Nayak, Trump et al. 2015). 
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1.10 Use of iPSCs for CN and CyN disorders 
Transplantation of allogeneic HSCs from healthy donors has been used as a 
potential source for treatment of congenital disorders. Autologous derived 
HSCs are a valid allogeneic source for in vitro genetic defect correction. 
Homologous recombination (HR) is currently among the advanced ways to 
restore a genetic defect because the HSC genome is only modified at the 
position of the mutation and repair by HR creates an identical phenotype as 
compared to heterozygous or hemizygous cells represent (Fig.13) (van 
Bekkum and Mikkers 2012).   
Due to the requirement of a selection process to identify the corrected cells 
by HR, this method considered as an inefficient and complicated procedure 
(van Bekkum and Mikkers 2012). In addition, the cells that have undergone 
proper HR modifications must be fully expanded to reach the required 
number for successful transplantation (van Bekkum and Mikkers 2012). 
Genetic modifications by viral vectors then HSCs differentiation from iPSCs 
due to the limited source of endogenous HSCs and contamination with T cells 
(GVHD) and a lack of HLA-matched engraftment are desired for treatment of 
congenital disorders  (van Bekkum and Mikkers 2012). 
Autologous iPSCs are always available and genetic corrections by a viral 
vector or using homologous recombination is possible, moreover the 
concerns regarding long-term repopulating of iPSCs derived from HSCs that 
have not been generated safely have been minimized by episome-
reprogrammed iPSCs methods (van Bekkum and Mikkers 2012). 
Figure 12. Clinical applications of the patient-specific induced pluripotent stem cells (iPSCs) 
 Somatic cells are reprogrammed into patient-specific iPSCs using reprogramming factors. Different methods 
could be used for genome editing of genetic defects in iPSCs. iPSCs with or without genomic modifications could 
be differentiated into various cells for the reason of disease modeling, stem cell therapy and drug screening 
(Source from Dieck S. et al. 2014). 
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2 Aims 
The main aims of this project were: 
To evaluate the role of TPO/c-mpl on the early hematopoietic differentiation of 
mouse ES cells.  
To evaluate the in vitro myeloid differentiation of iPSCs derived from the CyN 
patient harboring a sporadic heterozygous ELANE mutation (c.761C>G 
p.W241L) in comparison to iPSCs derived from a healthy individual and a CN 
patient harboring an ELANE mutation (p.C151Y). 
Figure 13. iPSCs based opportunities for HSC transplantation  
Left: Healthy individuals derived iPSCs that can be used as HLA-specific iPSCs banks. genetically modified by 
gene therapy strategies and mild GVHD due to the autologous sources can be used to treat hematopoietic 
disorders.  
Right: Patient-specific derived iPSCs can be used for disease modeling, drug screening or for the treatment of 
congenital disorders (Source from Van Bekkum, D. W. and H. M. M. Mikkers 2012). 
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3 Material and Methods 
3.1 Material 
3.1.1 Reagents and chemicals  
Name 
Catalog 
Number Company 
Sodium Azide, 25 g 58032-256 Sigma-Aldrich   
Na Pyruvat 100 ml 511-003 PAA  
DMEM/F12 500 ml D6421-6X Sigma-Aldrich 
FCS 500 ml 50115 Biochrom 
Peni/Strepto 100 ml A2213 Biochrom 
L-Glutamine 100 ml K0283 Biochrom 
Trypan Blue Solution 0,4 15250-061 Life Technologies 
TeSR1 5850 
Stem Cell 
Technologies  
Lenti-X Concentrator 631232 Clontech 
Recombinant Human IL-3 50 µg 203-IL-050 R&D Systems 
Recombinant Human FGF-basic 100 µg 100-18C Peptrotech 
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Corning Matrigel Growth Factor 10 ml 354230 Corning 
PBS (12 x 500 ml) 882126 Biozym 
2-Mercaptoethanol 100 ml M6250 Sigma 
Stem Pro Accutase Cell Dissociation 
Reagent A11105-01 Life Technologies 
PCR Nucleotide Mix 10 x 200 µg 11814362001 Roche Lifescience 
Light cycler 480 SYBR Green Master Mix 4707516001 Roche 
Ethidium bromide solution 0,025 % HP47.1 Roth 
Triton x-100 Detergent Solution 28314 Pierce 
0,25% Trypsin-EDTA 25200-056 Gibco 
Knockout SR 500 ml 10828028 Life Technologies 
Gel Red NC9594719 Thermo Scientific 
Non-Essencial Amino Acids 11140-050 Gibco 
Pre-Seperation Filters  130-041-407 Miltenyi 
D-MEM F-12 D6421-6X Sigma 
Insulin-Transferrin-Selenium  41400-045 Gibco 
Random Hexamer Primer S0142 Thermo Scientific 
B-27 Supplement (50x) 17504-044 Life Technologies 
N-2 Supplement (100x) 17502-048 Life Technologies 
mTeSR1 500ml 05850 
Stemcell 
Technologies 
MethoCult H4435 Enriched Medium 100 
ml 04435 
Stemcell 
Technologies 
APEL Medium 100 ml 05210 
Stemcell 
Technologies 
MACS Rinsing Solution 130-091-222 Miltenyi 
Hematoxylin solution 500 ml T865.2 Roth 
Eosin solution 500 ml X883.2 Roth 
DMEM FG 0435 
Biochrome 
Millipore 
FCS S0115 
Biochrome 
Millipore 
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DMEM (1x) 41966029 Gibco 
L-Glutamine 200 mM K0283 Biochrome 
Fetal Bovine Serum S0115 Biochrome 
DMSO 100 ml D2650 Sigma 
Y-27632 dihydrochloride 10 mg 1254 R&D Systems 
Ethylenediaminetetraacetic acid disodium 
salt dihydrate E4884-100G Sigma 
BCIP B8503 Sigma 
NBT N5514-10TAB Sigma  
Polyvinyl alcohol P8136-250G Sigma 
DMEM high glucose, pyruvate 41966-052 Thermo Fisher 
IMDM, no phenol Red 21056023 Thermo Fisher 
Ham's F12 nutrient mixture 31765035 Thermo Fisher 
PFHM-II Protein Free Hybridoma Medium 12040077 Thermo Fisher 
Chemically Defined Lipid Concentrate 11905031 Thermo Fisher 
N, N-Dimethylformamide D4551 Sigma 
Recombinant human FGF-8 100 µg 100-25 PeproTech 
Recombinant human BMP-4 50 µg 314-BP-050 R&D Systems 
Recombinant human VEGF 165 50 µg 293-VE-050 R&D Systems 
Recombinant human SCF/c-Kit Ligand 
200 µg 255-SC-200 R&D Systems 
Recombinant human TPO 200 µg 288-TP-200 R&D Systems 
Recombinant human IL-3 50 µg 203-IL-050 R&D Systems 
Recombinant human Noggin 25 µg 1967-NG025 R&D Systems 
Recombinant human IL-6 10 µg 206-IL-010 R&D Systems 
Recombinant human FLT3 Ligand 25 µg 308-FK-025 R&D Systems 
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3.1.2 Kits 
3.1.3 Antibodies  
Name Catalog Number Company 
Human CD34 Cell Nucleofector Kit VPA-1003 Lonza 
P3 Primary Cell 4D-Nucleofector X Kit L V4XP-3024 Lonza 
 
   
 
   
Name Catalog Number Company 
   
Rabbit anti-human SOX1 22572 Abcam 
Rabbit anti-human PAX6 SC11357 Santa-Cruz 
Rabbit anti-human G-CSFR Sc-694 Santa-Cruz 
Rabbit anti-human C-kit (C-19) Sc-168 Santa-Cruz 
Texas red goat anti-rabbit 2780 Santa-Cruz 
Mouse anti-human FLK-1 (A-3) SC-6251 Santa-Cruz 
Mouse anti-human GATA-2 (CG2-96) SC-267 Santa-Cruz 
Mouse anti-human  ß Tubulin III F8660-100 Sigma-Aldrich 
Anti-human CD33 MicroBeads 130-045-501 Miltenyi 
Anti-human TRA-1-60 Biotin 
conjugated 13-8863-82 
eBioscience 
affymetrix 
Alexa Fluor 488 Phalloidin A12379 Life Technologies 
Alexa Fluor 647 anti-human CD309 
(VEGFR2) 359910 Biolegend 
Alexa Fluor 488 anti-human CD309 
(VEGFR2) 359913 Biolegend 
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BV510 mouse anti-human CD45 
Antibody 304036 Biolegend 
BV421 mouse anti-human CD33 
antibody 303416 Biolegend 
APC-H7 mouse anti-human CD14 
clone My P9 560180 BD Biosciences 
PE-Cy7 mouse anti-human CD11b 301322 Biolegend 
PE mouse anti-human TRA-1-60 12-8863-80 eBioscience 
PE mouse anti-human CD34 (AC136) 130-081-002 Miltenyi 
PE mouse IgM Isotype Control 555584 BD Biosciences 
PE mouse anti-human CD34 550619 BD Biosciences 
PE mouse anti-human CD 11b 557321 BD Biosciences 
PE mouse Anti-human CD15 Clone 
HI98 555402 BD Pharmingen 
PE mouse anti-human CD43 560199 BD  Biosciences 
PE mouse anti-human CD177 564239 BD  Biosciences 
PE-Cy7 mouse anti-human CD34 
Clone 8G12 348811 BD  Biosciences 
FITC mouse anti-human CD 235a 559943 BD Biosciences 
FITC mouse anti-human CD41a 557296 BD Biosciences 
FITC mouse anti-human TRA-1-85 FAB3195F R&D Systems 
FITC mouse anti-human CD16 555406 BD  Biosciences 
FITC mouse anti-human CD33 
Antibody 555626 BD Biosciences 
FITC goat anti-mouse AP308F Chemicon 
FITC goat anti-rabbit AP308F Merck Millipore 
FITC Mouse anti-human CD34 clone 
581 555821 BD  Biosciences 
Propidium Iodide P3566 Life Technologies 
7-AAD 559925 BD Biosciences 
DAPI D1306 Life Technologies 
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3.1.4 Real time PCR primers 
GAPDH  CTGGGCTACACTGAGCACC 
AAGTGGTCGTTGAGGGCAATG 
 
PRE  GAGGAGTTGTGGCCCGTTGT 
TGACAGGTGGTGGCAATGCC 
 
NANOG  CAGGTGTTTGAGGGTAGCTC 
CGGTTCATCATGGTACAGTC   
 
SOX2  TTCACATGTCCCAGCACTACCAGA 
TCACATGTGTGAGAGGGGCAGTGTGC   
 
ABCG2  TACCTGTATAGTGTACTTCAT 
GGTCATGAGAAGTGTTGCTA  
 
DNMT  ATAAGTCGAAGGTGCGTCGT 
GGCAACATCTGAAGCCATTT  
 
PAX6  ACCCATTATCCAGATGTGTTTGCCCGAG 
ATGGTGAAGCTGGGCATAGGCGGCAG 
  
TUB III  TAGACCCCAGCGGCAACTAT 
GTTCCAGGTTCCAAGTCCACC  
 
MYH6  GCCCTTTGACATTCGCACTG 
GGTTTCAGCAATGACCTTGCC 
 
BRACH  CTGGGTACTCCCAATGGGG 
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3.1.5 Softwares 
Blast                 http://www.ncbi.nlm.nih.gov 
         flowJo              http://www.flowjo.com 
 
GGTTGGAGAATTGTTCCGATGA 
FOXA2  TGGGAGCGGTGAAGATGGAAGGGCAC 
TCATGCCAGCGCCCACGTACGACGAC 
 
AFP  GAATGCTGCAAACTGACCACGCTGGAAC 
TGGCATTCAAGAGGGTTTTCAGTCTGGA 
 
NAMPT AGGGCTTTGTCATTCCCAGA 
GCCAGCAGTCTCTTGGGAAG 
 
SIRT1 CAACTTGTACGACGAAGAC 
TCATCACCGAACAGAAGG 
 
SIRT2 GGCAGTTCAAGCCAACCATC 
AGCTTAGCGGGTATTCGTGC 
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3.2 Methods 
3.2.1 Transfection of HEK 293T cells for OSKM virus production 
HEK-293T cells were split 1 day before transfection with a confluency of 3× 
106 cells/T75 flasks in 10 ml of HEK medium as shown below. On the day of, 
reprogramming medium was replaced with 10 ml of TFM medium (T293T 
medium containing 2% of 1 M HEPES) supplemented with 25 mM 
chloroquine (25 µM final concentration) and cells were incubated until 
transfection (Tiscornia, Singer et al. 2006). 
 
 
 
Plasmid mixture containing 10 µg of OSKM lentiviral vector (Schambach, 
Bohne et al. 2006, Warlich, Kuehle et al. 2011) (Fig. 14 a,b), 15 µg of 
packaging plasmid (10 µg GagPol,  5 µg Rsv-Rev) and 6 µg of VSVG 
envelope plasmid were mixed with 50 µl of 2.5 M CaCl2 and refilled with water 
up to 0,5 ml. 0,5 ml of 2x HBS buffer (50 mM HEPES, 1.5 mM Na2HPO4,280 
mM NaCl, pH 6,95-7.0) was added to the plasmid mixture while bubbling with 
pasture pipette and the final cocktail was added into the cell culture flask after 
20 min incubation at room temperature.   
 
HEK-293T medium plasmid mixture  
DMEM high Glu medium  4,5 g/l 20 µg OSKM 
1% L-Glut 10 µg GagPol 
1% P/S 5 µg Rsv-Rev 
1% Natrium Pyruvate 6 µg VSVG 
10% FBS heat inactivated 2.5 M CaCl2 50  µl 
0,1 mM ß-Mercaptoethanol Water up to 500 µl 
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Supernatant was collected after 24, 36 and 42 hours and filtered (0,45-
micrometer pore size). Virus particles were concentrated by lenti-X 
concentrator according to manufacturer protocol. 
 
 
 
 
b 
Figure 14. OSKM virus structure 
a, Schema of OSKM virus; b, OSKM vector map (Source from Warlich et al. 2011). 
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3.2.2 Differentiation of mouse ES cells into hematopoietic lineage 
The maintenance of mouse ES cells carried out by using of medium containing 
DMEM basal medium supplemented with 10% fetal calf serum (FCS) and LIF 
(1,000 U/mL, Chemicon) on inactivated MEF feeder cells (Pramono, Zahabi et al. 
2016). 
Hematopoietic differentiation of mouse ES cells (E14) was induced by 
trypsinization and seeding of the cells into bacterial dishes (2 x 105 cells per 3cm 
dish) in IMDM basal medium supplemented with 10% FCS for generation of 
embryoid bodies (EBs) from the ES cells. Thrombopoietin (TPO) cytokine was 
added in 10 ng/mL concentration to the EBs medium and non-treated cytokine 
group considered as a control group (Pramono, Zahabi et al. 2016).  
 
3.2.3 Reprogramming of CD34+ cells and fibroblasts in iPSCs using 
lentivirus-based transduction of OSKM plasmids 
Plates were coated with Retronectin (Takara) one day before transduction 
(overnight at 4°C). On the day of reprogramming, Retronectin was aspirated 
and virus at MOI between 2 to 4 was added to the plates followed by 
centrifugation for 2h at 2000g, +4°. Supernatant was aspirated and 5x105 of 
CD34+ cells were plated in CD34+ expansion medium centrifuged for 20 min 
(1200 rpm 32°C). Plates were incubated  in a wet chamber at 37°C and 
CD34+ expansion medium was added every day till day 4-5 of 
reprogramming. After the appearance of positive transduction signal, cells 
were split in 3 cm SNL coated plates in CD34+ expansion medium. The iPSCs 
medium was gradually replaced every day until the appearance of the first 
iPS colonies (Fig.15).   
Fibroblasts were thawed and cultured for 1 week in fibroblast cell culture 
medium. Fibroblasts were plated  in a 6-well plate (5×104 cells/ well) one day 
before reprogramming. OSKM virus at an MOI 2-4 was added to the cells 
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(Arai, Takada et al. 1999). The addition of the protamine sulfate (4ng/ml) and 
50 µg/ml of vitamin C improved the reprogramming procedure. Fibroblast 
medium was changed the next day. After the appearance of the transduction 
signal, cells were split (density of 1:3 or 1:6) and transferred on SNL feeders 
culture. The medium was gradually switched to HESCs medium. Colonies of 
iPSCs appeared on day 18-30 of culture (depends on the fibroblast quality –
doubling time). 
In both fibroblasts and CD34+ reprogramming, 4-5 iPSCs colonies were 
selected for maintenance, characterization and differentiation analysis. 
 
Figure 15. Experimental strategy used in the generation of hiPSCs from CD34+ cells using OSKM 
lentivector. 
Tranceduced CD34+ cells will be plated on feeders three days after tranceduction and by ten days, emergence 
of first iPS colonies could be detected on the feeder cells (Source from V Ramos-Mejía et al. 2012). 
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3.2.4 hiPSCs maintenance  
hiPSCs colonies need to be passaged every 8-10 days. There are different 
ways for passaging of iPSCs including enzymatic and non-enzymatic 
methods (Kibschull, Mileikovsky et al. 2011, Beers, Gulbranson et al. 2012). 
For passaging of iPSCs, 12-15 colonies were scratched off the dish and 
transferred into 6 mL hiPSCs maintenance medium. The colonies were then 
carefully dissociated into smaller aggregates and seeded into the 6 cm dishes 
with the SNL feeder layer prepared one day before. The medium was 
changed every day. 
 
3.2.5 Hematopoietic differentiation of iPSCs 
iPSCs from healthy individuals, CyN and CN patients were differentiated into 
hematopoietic cells through embryoid bodies (EBs) based formation, in a 
feeder-free method (Fig. 16). The cytokine mix was changed in a stepwise 
manner to recapitulate early embryonic development. 
In the first step, which is EB formation, iPSCs colonies after 10-12 days of 
maintenance were treated with 0.02% of PBS-EDTA for 5-7 minutes. After 
removing PBS-EDTA, single cells were harvested by gently pipetting in 1-2 
ml APEL basal medium. 2 × 104 of cells were split into a 96 well plate 
containing 100 µl of APEL medium with 20 ng/ml of basic fibroblast growth 
factor (bFGF) and 10 µM Rock inhibitor (Y-27632). Cells were centrifuged at 
1500 rpm for 5 minutes at +5 °C. On day two of the experiment (step 2), 100 
µl of APEL medium containing 40 ng/ml of BMP4 and bFGF were added to 
each well (final concentration of relevant cytokines should rich concentration 
of 20ng/ml). On day 4 (step 3), EBs were plated on matrigel-coated wells (10 
EBs per well) in 1,5 ml APEL medium supplemented with 40 ng/ml VEGF, 50 
ng/ml SCF and 50 ng/ml IL-3 final concentrations. 
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step 1, day 1 
EB induction
Spin down cells in 
cone shaped 96 
wells using APEL 
medium containing:
20 ng/ml  bFGF,
10 µM Rock  
Inhibitor 
step 2, day 2
Mesoderm  
induction
Addition of APEL 
medium containing
20 ng/ml final 
concentrations of 
BMP-4 and 
bFGF 
step 3, day 4
EB Plating on 
matrigel
In APEL medium 
supplemented with: 
40 ng/ml VEGF,
50 ng/ml SCF,
50 ng/ml IL-3
step 4, day 7 
neutrophil
maturation
changing medium 
using APEL medium 
containing:
50 ng/ml IL-3 and 
50 ng/ml G-CSF 
On day 7 of the experiment (step 4), half of the medium was changed using 
APEL medium supplemented with 50 ng/ml of IL-3 and 50 ng/ml of G-CSF. 
Every second day a half of the medium was changed and IL-3 and G-CSF 
were added up to the final concentrations of 50 ng/ml. After 14 days of culture, 
EBs started to release floating hematopoietic cells. Floating cells were 
collected for FACS analysis at defined time points. 
 
 
 
3.2.6 Flow Cytometry  
iPSCs were characterized using evaluation of SSEA4 and Tra1-60 as surface 
pluripotency markers of iPSCs (Draper, Pigott et al. 2002) by FACS. 
Briefly, iPSCs on day 7-8 of culture were harvested after 7 minutes of 
treatment with acutase and washed with PBS (400g for 5min). For each 
sample, 1×104- 2×104 cells were resuspended in 50μl of FACS buffer (PBS 
with 1% BSA) and were incubated in related antibody for 20 minutes. The 
anti-human Tra1-85 antibody was used as a detector marker between human 
and mouse cells. Finally, cells were washed and resuspended in 200 μl of 
Figure 16. Schema of differentiation protocol of hiPSCs into mature neutrophils. 
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FACS buffer containing 1 μl/ml of DAPI as a nuclear marker. Measurements 
were performed on FACS Canto II system.  
The early and late antibody panel were used for detection of hematopoietic 
differentiation at different time points (shown below). The phenotype of cells 
was studied using monoclonal antibodies against the appropriate antigens. 
The results were obtained using multicolor FACS using compensation 
controls with compensation beads. Analysis of the experiments was 
performed using the FlowJo software package (Version 10.0.8r1, Tree Star, 
and Ashland, OR, USA). 
3.2.7 Alkaline phosphatase activity assay 
iPSCs were tested for alkaline phosphatase enzyme activity (O'Connor, 
Kardel et al. 2008). Using NBT/BCIP staining protocol briefly, iPS plates were 
washed with PBS and fixed using 2 ml of 4% PFA per 6cm plate for 2 min 
then washed again with PBS. NBT/BCIP (15ml containing: 550 µl NBT, 52,5 
µl BCIP and fill up to 15 ml NTM buffer (0,1M Tris pH 9,5 (121,14 g/mol), 
0,1M NaCl (58,44 g/mol), 0,05M MgCl (95,21 g/mol) made and stored in 4°C 
staining dye was added to 6 cm plates for 20 min at  RT in the dark place. 
After incubation, each plate was washed with PBS and stored at +4°C.  
Early stage of hematopoietic 
differentiation Antibody panel 
Late stage of hematopoietic 
differentiation  Antibody panel 
CD34 PE-cy7 CD11b PE-cy7 
CD235a FITC CD15 PE 
CD41a FITC CD16 FITC 
CD45 BV510 CD45 BV510 
7AAD nuclear marker 7AAD nuclear marker 
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3.2.8 Quantitative real-time RT-PCR (qRT-PCR) 
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-
PCR) was performed by QIAGEN RNeasy Mini Kit (Qiagen), as described by 
the manufacturer protocol. The cDNA was synthesized using random 
hexamer primers and the mRNA expression was measured using SYBR 
Green qPCR Kit (Qiagen). After normalization to ß-actin or GAPDH or to 
RSP9, the target genes mRNA expression were expressed as fold change 
and were represented as arbitrary units (AU) or fold change.  
3.2.9 Western blot analysis 
Cell lysates were obtained through lysis of the cells in Laemmli buffer and 
loading buffer. Proteins were separated on 10% SDS-PAGE and the binding 
was detected by ECL. 
 
3.2.10 DUOLINK using in situ proximity ligation (PLA) assay 
ES cells cultured with 10 ng/ml of TPO treatment for 1,5 days, used for Duolink 
In Situ Proximity Ligation (PLA) Assay (Olink Bioscience, Uppsala, Sweden). In 
this experiment treated cells were detected for Endogenous expression of HIF-
1α protein, as described by the manufacturer. 
 
3.2.11 Statistical analysis 
Differences in mean values between groups were analyzed using two-sided, 
unpaired Student’s t-tests using the Prism statistical package or the SPSS V. 9.0 
statistical package.  
 4 Results 
4.1 Evaluation of the mechanisms operating during the early stages 
of hematopoiesis using a mouse ES cells model 
4.1.1 TPO-induced hematopoietic differentiation evaluation of mouse 
ES cells 
Hematopoietic differentiation of the E14 mouse ES cell line has been 
performed by the embryoid bodies (EBs) formation experiment. For this 
reason generated EBs were plated in the medium containing of 10 ng/mL 
TPO and medium without TPO considered as a control group (Fig. 17a) 
(Pramono, Zahabi et al. 2016). 
mRNA expression of Flk-1 (early hematopoietic and vascular progenitors 
marker) was induced in EBs after one-day treatment with TPO and reached 
a maximum before two days. After three days of treatment with TPO, the Flk-
1 expression was decreased as shown in the figure 17b (Pramono, Zahabi et 
al. 2016).  
Interestingly, expression of the VEGF-A mRNA (vascular marker) was highly 
increased after TPO treatment of ES cells for one day (Fig. 17c). Mesoderm 
and hematopoietic differentiation after TPO treatment were confirmed 
through elevation of mRNA levels of brachyury gene as a responsible 
candidate for mesoderm formation and Runx1 for hematopoietic 
development (Fig. 17d) (Pramono, Zahabi et al. 2016).  
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Figure 17. Induction of hematopoietic differentiation of mouse ES cells by TPO 
 a, schema of hematopoietic differentiation of the E14 mouse ES cell line. b, c evaluation of the mRNA 
expression for Flk-1 and VEGF-A in the TPO treatment or non-treatment groups is normalized to GAPDH or 
RSP9. Data is represented as arbitrary units (AU) and means ± s.d. Samples derived from four individual 
experiments each in triplicates (*, P< 0.05; **, P< 0.01); d, mRNA expression of Brachury and Runx1 genes 
quantified and normalized to GAPDH and is presented as arbitrary units (AU). data are derived from three 
individual experiments each in triplicates and is represented by means ± s.d. (*, P< 0.05; **, P< 0.01) (Source 
from Pramono, Zahabi et al. 2016). 
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4.1.2 Up-regulation of c-mpl receptor by TPO in mouse EBs 
Untreated cells represented a low level of TPO receptor c-mpl mRNA and 
protein as compared to c-mpl mRNA and protein increased levels in EBs after 
treatment with TPO (Fig. 18a,b) (Pramono, Zahabi et al. 2016).   
This finding shows that TPO-receptor c-mpl can be up-regulated after TPO 
treatment of ES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
4.1.3 Activation of BMP4 autoregulation in mouse ES cells by TPO 
During the first days of treatment with 10 ng/ml TPO, we found that Flk-1 
expression was highly induced in EB culture. Therefore, downstream of 
Figure 18. Up-regulation of TPO-receptor, c-mpl after treatment of mouse ES cells by TPO 
a, c-mpl mRNA expression levels is normalized to GAPDH and is represented as arbitrary units (AU). data 
represent means ± s.d. and are derived from four individual experiments each in triplicates (*, P< 0.05; **, P< 
0.01); b, graphic bars of the ratio between the optical density of protein bands of c-mpl protein expression to the 
house-keeping protein, β-actin in western blot analysis 1.5 day after treatment with TPO (Source from Pramono, 
Zahabi et al. 2016). 
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TPO/c-mpl signaling pathway, were evaluated to investigate the role of TPO 
in the early hematopoietic differentiation of ES cells, in the next step 
(Pramono, Zahabi et al. 2016).     
The mRNA expression profiles of BMP4 and the BMP4 target genes in the 
Flk-1 expressing or non-expressing mouse ES cells were evaluated. We 
found a highly up-regulation in the mRNA levels of these genes in Flk-1 
expressing but not in Flk-1 non-expressing cells upon TPO treatment (Fig. 
19) (Pramono, Zahabi et al. 2016). These data confirms the role of TPO in 
the development of mouse ES cells derived early hematopoiesis.  
 
 
 
 
 
 
 
 
 
 
Figure 19. TPO upregulates the BMP4 during hematopoietic differentiation of mouse ES cells 
a, mRNA expression levels of BMP4, c-mpl and Id1 in Flk-1 expressing cells as compared to Flk-1 non-
expressing cell was normalized to GAPDH. Data is presented as arbitrary units (AU) and are derived from two 
individual experiments each in triplicates and is represented by means ± s.d. (Source from Pramono, Zahabi et 
al. 2016).  
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4.1.4 The binding of HIF-1α to the BMP4 gene promoter is induced by 
TPO in mouse ES cells 
In silico, functional analysis of the BMP4 gene promoter was performed in 
order to understand the molecular mechanisms of TPO treatment on BMP4 
synthesis (Fig.20).  
Two putative highly conserved binding sites (at the positions –142 bp to –130 
bp and –140 bp to –128 bp) for HIF-1α were identified (Fig. 20a) (Pramono, 
Zahabi et al. 2016). This data confirmed the enhancement of HIF-1α protein 
stability by TPO in primitive hematopoietic cells.  
In addition, endogenous HIF-1α protein expression after 1,5 days treatment 
of ES cells with 10 ng/ml TPO was detected using DUOLINK based on in situ 
proximity ligation (PLA), which is a proximity ligation assay. DUOLINK data 
confirmed the enhancement of HIF-1α protein by TPO treatment of the EC 
cells as compared to non-treated control (Fig. 20b). 
Altogether, this data indicates that TPO regulates BMP4 signaling via HIF-1α 
transcription factor and induces stabilization and binding of HIF-1α to the 
BMP4 gene promoter (Pramono, Zahabi et al. 2016). Induction and secretion 
of BMP4 in an autoregulation pattern induce the upregulation of BMP4 
downstream signaling target genes and induction of early hematopoietic 
differentiation of ES cells (Fig. 20c) (Pramono, Zahabi et al. 2016). 
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Figure 20. Autocrine synthesis of BMP4 triggered by TPO and BMP4 downstream activation through 
HIF-1α to the BMP4 gene promoter binding 
  a, Alignment of the BMP4 upstream promoter with the HIF-1α binding region in the in silico experiment marked 
in red; b, In situ PLAs using anti-HIF-1α mouse monoclonal Ab were performed on cytospin slides prepared after 
1.5 days of TPO treatment of EBs. Untreated ES cells considered as control group e, Schema of TPO-dependent 
BMP4 regulation: stabilization of HIF-1α protein by TPO and binding of HIF-1α to the BMP4 gene promoter could 
activate the autocrine synthesis of BMP4 and its target genes that resultes in mouse ES cells derived early 
hematopoietic differentiation (Source from Pramono, Zahabi et al. 2016). 
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4.2 Evaluation of the mechanisms operating during late stages of 
hematopoiesis using iPSCs model 
4.2.1 Generation of iPSCs using Amaxa 4D nucleofector system 
Episomal iPSCs were generated using Amaxa nucleofector 4D (EN-150 
program) from either CD34+ or fibroblasts of healthy individuals (Fig. 21a). 
Generated iPSCs colonies were tested for pluripotency markers such as 
alkaline phosphatase activity (Fig. 21b) and surface expression of SSEA-4 
and Tra1-60 (Fig. 21c,d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
a b 
c d 
SSEA-4 Tra1-60 
T
ra
1
-8
5
 
T
ra
1
-8
5
 
Figure 21. Generation of iPSCs using Amaxa nucleofector 4D 
a, representative image of iPSCs derived from healthy human CD34+ cells using AMAXA nucleofection; b, 
representative image of alkhaline phosfatase activity assay of iPSCs derived from healthy human CD34+ cells; c, 
SSEA-4 (PE)-Tra 1-85 (FITC) or d, Tra1-60 (PE)-Tra 1-85 (FITC) co-expression on iPSCs derived from healthy 
human CD34+ cells. 
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4.2.2 Generation of iPSCs from CN and CyN patients carrying ELANE 
mutations using OSKM lentivirus 
Fibroblasts or CD34+ cells (Fig. 22a,d, respectively) from CyN or CN patients 
harboring ELANE mutations as well as from healthy individuals were 
reprogrammed using OSKM lentivirus (Schambach, Bohne et al. 2006) into 
iPSCs. Three to five days after transduction of cells using OSKM lentivirus, 
the red signal was appeared in transfected cells (Fig. 22b,e), iPS colonies 
were generated within 8-10 days after plating on SNL feeder cells (Fig. 22c,f), 
which was 2-3 times faster than episomal based reprogramming. In both 
fibroblasts and CD34+ reprogramming conditions, 4-5 of the best iPS colonies 
were selected for further characterization and differentiation. The efficiency 
of OSKM lentivirus-based reprogramming was 30-40% higher than that of the 
episomal reprogramming method.  
 
 
 
 
  
 
 
 
 
 
 
Figure 22. Generation of iPSCs using OSKM lenti virus  
a, representative image of human healthy fibroblast used for generation of iPSCs b, representative image of 
human healthy fibroblast transduced by OSKM lenti virus on day 5 of culture c, representative image of hiPSCs 
generated from fibroblasts by OSKM transduction d, representative image of human healthy CD34+cells used for 
generation of iPSCs e, representative image of human healthy CD34+cells transduced at day 5 using OSKM lenti 
virus f, representative image of iPSCs generated by OSKM transduction. 
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4.2.3 mRNA expression levels of pluripotency markers in iPSCs 
mRNA expression levels of the iPSCs pluripotency genes such as NANOG 
and ABCG2 were evaluated on day 7-8  of iPSCs culture using qRT-PCR. As 
expected, mRNA expression levels of NANOG and ABCG2 were markedly 
increased in iPSCs derived from cells of CN and CyN patients as well as from 
a healthy individual, as compared to the expression levels of these markers 
in the original cells (Fig. 23a-d). 
We also evaluated silencing of the OSKM lentivirus after iPSCs generation 
using primers that amplify the PRE region of the vector. We compared PRE 
expression in untransduced fibroblasts and CD34+ cells, in these cells on day 
5 after transduction and in undifferentiated iPSCs (Fig. 23e,f).  Indeed, we 
found the highest expression levels of PRE in CD34+ cells and in fibroblasts 
on day 5 after transduction, which were markedly declined in iPSCs. 
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Figure 23. Pluripotency gene expression analysis 
mRNA expression levels of the indicated genes in the undifferentiated iPSCs on day 7 of culture was assessed 
using qRT-PCR. a-b Nanog mRNA levels, fold increase of CyN compare to healthy individual and fibroblasts and 
CN compare to healthy individual and CD34+ cells c-d ABCG2 mRNA levels, fold increase of CyN compare to 
healthy individual and fibroblasts and CN compare to healthy individual and CD34+ cells e-f PRE mRNA levels, 
fold increase of CyN at day 5 of reprogramming compare to healthy individual and fibroblasts or PRE mRNA 
levels, fold increase of CN at day 5 of reprogramming compare to healthy individual and CD34+ cells. Fold change 
in fibroblast or CD34+ undifferentiated cells was taken as 1. Data are means ± s.d. and are derived from three 
independent experiments, each in triplicate. By analysis of PRE expression in generated iPSCs, OSKM vector 
silencing monitored, as compared to day 5 of reprogramming. Fib: fibroblasts; D5: day 5 of reprogramming; H9: 
Standard human embryonic stem cell line. 
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4.2.4 Surface expression level of pluripotency markers in iPSCs  
iPSCs were analyzed for SSEA4 and Tra1-60 surface marker expression on 
day 7-10 of culture. We found that more than 85 % of iPSCs generated from 
the healthy individual (Fig.24a), CyN patient (Fig.24b) or CN patient (Fig.24c) 
expressed SSEA4 and Tra 1-60 surface markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 24. Representative histogram plots of SSEA4 and Tra1-60 surface marker expression on iPSCs 
measured by FACS 
blue: isotype control, pink SSEA4 and Tra1-60 staining a, healthy individual SSEA4 and Tra1-60 surface marker 
expression b, SSEA4 and Tra1-60 surface marker expression on CyN derived iPSCs c, SSEA4 and Tra1-60 
surface marker expression on CN patient derived iPSCs. 
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Figure 25. Alkaline phosphatase activity assay 
a,b,c representative images of alkaline phosphatase staining of healthy individual derived iPSCs (a) CyN 
derived iPSCs (b) and CN derived iPSCs (c). 
 
4.2.5 Alkaline phosphatase staining  
Alkaline phosphatase activity test of iPSCs revealed that all iPSCs colonies 
generated by us were positive for this stemness indicator marker (Fig. 25a,b,c). 
 
 
 
 
 
 
 
 
 
4.2.6 Verification of Germ Layer Markers in Differentiated Pluripotent 
Stem cells 
 Immunofluorescence staining of markers characteristic for three different 
germ layers (Sox17 – marker of early and defined endoderm; Tubulin III – 
marker of ectoderm; desmin – marker of mesoderm) after three weeks of 
spontaneous differentiation via embryoid bodies of healthy individual, CyN 
and CN derived iPSCs demonstrated that iPSCs clones are able to 
differentiate into three germ layers (Fig. 26).  
.  
 
a b c 
66 
 
Figure 26. Spontaneous differentiation of iPSCs into three germ layers  
Representative images of Immunocytochemistry staining of TUBIII expression as ectodermal marker and 
Sox17 as endodermal marker and Desmin as mesodermal marker for helthy individual, CyN and CN derived 
iPSCs.  Nuclei (blue) were counterstained with 4,6-diamidino-2-phenylindole (DAPI).  
 
 
 
 
 
 
 
 
 
 
4.2.7 Establishment of the EB-based protocol for myeloid 
differentiation of human iPSCs 
We first established the EB-based system of myeloid differentiation of iPSCs 
in our lab using iPSCs clones generated from fibroblasts of a healthy donor 
(Ng, Davis et al. 2008, Lachmann, Happle et al. 2014). EBs were formed by 
spin-down of single iPSCs in the cone shaped 96 well plates (Fig. 27a,b). 
EBs were cultured in APEL medium with a step-wise addition of cytokine 
mixtures, as described in the Material and Methods section. We found that 
floating hematopoietic cells appeared on day 13 - 15 of EB culture. Floating 
cells were collected every 3-4 days and the system continuously generated 
floating cells for up to 35 days (Fig. 27c). Cell morphology of cytospin 
preparations of floating cells from day 18 or 20 of culture clearly 
demonstrated the presence of mature granulocytes (Fig. 27d).  
FACS analysis of floating cells collected on day 13-15 of culture revealed only 
one population of cells that consists of mature granulocytes and not yet 
completely differentiated myeloid cells (Fig. 27e). Interestingly, FACS 
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analysis of floating cells collected on day 18-20 of culture revealed two cell 
populations (Fig. 27f). Cell sorting and morphology examination of these two 
cell populations demonstrated that the upper population (P2) consisted of 
dying myeloid cells that don’t express neutrophil markers such as CD15 or 
CD16 and the lower population (P1) contained living myeloid cells with high 
expression of mature neutrophil markers. Therefore, for further analysis of 
granulocytic differentiation we used the lower (P1) population of myeloid 
cells. 
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Figure 27. Granulocytic differentiation of iPSCs 
 a, iPSCs colony on day 10 b, spin down EB formation at day 1 c, appearance of hematopoietic colonies from 
day 15 of hematopoietic differentiation culture d, Wright-Giemsa–stained images of cytospin preparations from 
iPSCs derived hematopoietic e, FACS analysis of floating cells collected on day 13-15 of culture revealed only 
1 population of hematopoietic cells f, FACS analysis of floating cells collected on day 18-20 of culture revealed 
2 populations of graulocytes. 
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4.2.8 Evaluation of NAMPT and G-CSF on hematopoietic 
differentiation of hiPSCs 
Previously our group demonstrated that nicotinamide 
phosphoribosyltransferase (NAMPT) is essential for the G-CSF-induced 
myeloid differentiation of human hematopoietic CD34+ cells via an NAD+-
sirtuin-1-dependent pathway (Skokowa et al., 2009). Therefore, we evaluated 
the role of G-CSF and NAMPT on the myeloid differentiation of iPSCs using 
our EB-based differentiation system. We used different culture conditions, as 
described in Figure 29. Briefly, on day 4 of differentiation (step 3), in addition 
to VEGF and SCF, further cytokines were added to the EB culture, as 
followed: (1) medium alone (control); (2) IL-3 (50 ng/ml) alone (standard 
conditions); (3) NAMPT (50 ng/ml) alone; (4) G-CSF (50 ng/ml) alone; (5) IL-
3+G-CSF or (6) IL-3+NAMPT. Myeloid differentiation was assessed on day 
13 and 20 of culture by FACS (Fig. 28). 
 
 
 
 
 
 
 
We found that cell count was dramatically decreased when we omitted IL-3 
from the culture (Fig. 29a). We observed an increase in surface marker 
expression by day 20 in all groups, but absolute cell count results revealed 
that IL-3 has the most important role on proliferation and myeloid 
differentiation of iPSCs (Fig. 29b,c,d) 
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Mesoderm 
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maturation
Figure 28. Schema of hematopoietic differentiation of iPSCs to evaluate the effect of NAMPT, G-CSF 
and IL-3  
 Different cytokine mixture evaluated in presence or absence of IL-3 as the main hematopoietic differentiation 
cytokine to test whether NAMPT or G-CSF has any effect on proliferation or maturation of hematopoietic cells. 
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We found that G-CSF alone was able to induce differentiation of 
CD45+CD11b+, CD45+CD15+ and CD45+CD16+ myelo-granulocytic cells 
(Fig. 30b-d) on day 13 and day 20 of culture, as compared to the control 
group (Fig. 29c). NAMPT alone also slightly induced the generation of 
CD45+CD15+ and CD45+CD16+ myelo-granulocytic cells, but to a lesser 
extent as compared to the IL-3 and G-CSF groups. The addition of NAMPT 
to IL-3 did not have any synergistic effects on IL-3 and addition of G-CSF to 
IL-3 slightly enhanced myelo-granulocytic differentiation of iPSCs (Fig. 29). 
Altogether, we concluded that IL-3+G-CSF is the best condition to improve 
our neutrophil maturation protocol for further experiments applicable for CN 
patients derived iPSCs lines. 
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Figure 29. Shema of NAMPT and G-CSF effect evaluation on hematopoietic differentiation of hiPSCs 
 a, graphic bar represents the cell count of the experiment on different cytokine groups at day 13 and 20 of 
experiment b, graphic bars represent the % of CD45+CD11b+ cells and absolute cell count evaluation of each 
group c, graphic bars represent the % of CD45+CD16+ cells and evaluation of absolute cell count d, graphic bars 
represent the % of CD45+CD15+ cells and evaluation of absolute cell count. data represent means ± s.d. and are 
derived from two experiments in duplicates (*, P < 0.05; **, P < 0.01, ***, P < 0.001). 
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4.2.9 Evaluation of Nicotinamide (NA) as NAMPT substrate on 
hematopoietic differentiation of hiPSCs 
To evaluate the role of Nicotinamide (NA), as a substrate of NAMPT enzyme, 
in EB-based differentiation of hiPSCs, EBs were plated in APEL medium 
containing VEGF (40 ng/ml), SCF (50 ng/ml) and NA (50 nMol) or IL-3 (50 
ng/ml) on step 3 of culture (Fig. 30). Medium without any cytokines was 
considered as a control. Floating cells were collected on day 22 of culture for 
further evaluation of myeloid differentiation by FACS. 
 
 
 
 
 
 
 
We found that addition of NA alone resulted in a slightly increased total 
number of floating cells, as compared to the control group (Fig.31a), but using 
IL-3 the cell numbers dramatically increased. Addition of NA to the culture 
medium resulted in generation of low amounts of CD45+CD11b+ and 
CD45+CD15+ myelo-granulocytic cells (Fig.31b,d), while the effect of IL-3 
was considerable (Fig.31b,c,d). Based on these observations, we concluded 
that NA alone at a concentration of  (50 nMol) is not a proper factor for 
myeloid differentiation of iPSCs. 
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Figure 30. Schema of hematopoietic differentiation of iPSCs to evaluate the effect of NA in comparison 
to IL-3  
 NA as substrate of NAMPT enzyme was evaluated compare to IL-3 as the main cytokine group to test whether 
NA has any effect on proliferation or maturation of hematopoietic cells. 
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4.2.10 Evaluation of GM-CSF effect on hematopoietic differentiation of 
hiPSCs 
Recent studies demonstrated that GM-CSF and IL-3 possess in some 
aspects redundant, but in other, completely different functions. They share 
same β-chain receptor subunit, but different receptor α-chains (Kitamura, 
Sato et al. 1991, Sakamaki, Miyajima et al. 1992, Shearer, Rosenwasser et 
al. 2003) Therefore, we compared the effect of GM-CSF and IL-3 on the 
myeloid differentiation of hiPSCs using the EB-based differentiation system. 
For this, EBs were plated in APEL medium containing (1) VEGF (40 ng/ml), 
SCF (50 ng/ml) and GM-CSF (50 ng/ml) or (2) VEGF, SCF and IL-3 (50 
ng/ml)  in step 3 of our protocol (Fig. 32). Floating cells were collected on day 
22 of culture for further analysis by FACS. 
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Figure 31. Evaluation of NA effect on hematopoietic differentiation of hiPSCs 
a, graphic bar represents the cell count of the experiment in different groups at day 22 of experiment b, graphic 
bars represent the % of CD45+CD11b+ cells and absolute cell count evaluation of each group c, graphic bars 
represent the % of CD45+CD16+ cells and evaluation of absolute cell count d, graphic bars represent the % of 
CD45+CD15+ cells and evaluation of absolute cell count. data represent means ± s.d. and are derived from two 
experiments in duplicates (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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Interestingly, we found that GM-CSF-triggered myelo-granulocytic 
differentiation was similar to the IL-3-triggered differentiation (Fig. 33a-c). 
Therefore, we concluded that GM-CSF also has effects on both proliferation 
and myelo-granulocytic maturation of iPSCs in the EB-based system.  
In order to improve the EB-based myeloid differentiation of iPSCs derived 
from CN or CyN patients, we aimed to identify the best combination of 
cytokines for more efficient generation of granulocytes. We found that GM-
CSF could be also a good candidate to improve the differentiation system 
into granulocytes, but still IL-3+GCSF was the best cytokine combination that 
we could use for our CN or CyN patient-derived iPSCs. 
 
 
 
 
 
 
Step 1 
EB induction
Step 2
Mesoderm 
Induction
Step 3 
EB Plating in 
VEGF,SCF+ (GM-
CSF or IL-3)
Step 4 
analysis of 
neutrophil
maturation
Figure 32. Schema of hematopoietic differentiation of iPSCs to evaluate the effect of GM-CSF in 
comparison to IL-3  
 GM-CSF which has the same β chain receptor compare to IL-3 and shared some similar function was evaluated 
compare to IL-3 as the main cytokine group to test whether GM-CSF has any effect on proliferation or maturation 
of hematopoietic cells.  
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Figure 33. Evaluation of GM-CSF on hematopoietic differentiation of hiPSCs 
 a, graphic bars represent the % of CD45+CD11b+ surface markers and absolute cell count evaluation of each 
group c, graphic bars represent the % of CD45+CD16+ cells and evaluation of absolute cell count d, graphic bars 
represent the % of CD45+CD15+ cells and evaluation of absolute cell count. Data represent means ± s.d. and 
are derived from two experiments in duplicates. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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4.2.11 Comparison of hematopoietic differentiation of CyN, CN and 
healthy individual derived hiPSCs  
We further compared the EB-based myeloid differentiation of iPSCs derived 
from a healthy individual, with that derived from a CyN or CN patients. For 
this, we monitored the early and late stages of hematopoietic and myeloid 
differentiation using two multicolor FACS panels (Fig. 34). 
We found that EBs derived from iPSCs of a healthy individual and from a CyN 
patient continuously generated increasing numbers of floating hematopoietic 
and myeloid cells, while CN patient-derived iPSCs represent constant low cell 
numbers during in vitro differentiation (Fig. 34a). Interestingly, CyN patient-
derived  iPSCs did not show any cycling behavior during in vitro culture. 
Interestingly, the absolute counts of floating CD45+CD41a+ and CD45+CD34+ 
hematopoietic stem cells generated on day 15 and 18 of culture were 
comparable between iPSCs of the healthy donor and the CyN patient but 
were  markedly decreased  in iPSCs of the CN patient (Fig. 34b,c).  
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To evaluate myeloid differentiation of iPSCs of a healthy individual, CN 
patient and CyN patient, cells were collected on day 18, 28 and 32 of culture 
and were assessed by FACS. In this experiment, iPSCs derived from healthy 
individuals produced maximal numbers of myeloid and granulocytic cells on 
Figure 34. Evaluation of early hematopoietic differentiation differences between healthy individual 
and CyN or CN patients derived iPSCs 
 a, graphic bars represent the cell count of 3 different iPS cells at different time points. b, graphic bars 
represent the % of CD45+CD41a+ surface markers of each group and related absolute count of each group c, 
graphic bars represent the % of CD45+CD34+ cells and related absolute count of each group. Data represent 
means ± s.d. and are derived from two experiments in duplicates. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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day 28, but not on day 32 of culture. Most probably, EBs slowly stopped to 
differentiate on day 32. We detected diminished absolute numbers of 
CD45+CD11b+ myeloid cells and of granulocytic cells (CD45+CD16+) that 
were derived from iPSCs of the CyN patient, as compared to that of the 
healthy individual on day 28 of culture. We also found a remarkable reduction 
of absolute numbers of the myeloid and granulocytic cells that were 
generated from iPSCs of the CN patient, as compared to these cells of the 
healthy individual on day 28 of culture (Fig. 35a-d).  
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4.2.12 Cell morphology  
We further evaluated the cell morphology of Wright-Giemsa–stained cytospin 
preparations of myeloid cells generated on day 28 of culture from the 
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Figure 35. Evaluation of late hematopoietic differentiation differences between healthy individual and 
CyN or CN patients derived iPSCs  
 a, graphic bars represent the % of CD45+CD11b+ surface markers of each group and related absolute count 
of each group b, graphic bars represent the % of CD45+CD16+ cells and related absolute cell count of each 
group c, graphic bars represent the % of CD45+CD15+ cells d, graphic bars represent the % of CD15+CD16+ 
surface markers of each group and related absolute count of each group. Data represent means ± s.d. and are 
derived from the experiments in duplicates. (*, P < 0.05; **, P < 0.01; ***, P < 0.001). 
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b c a 
previous experiment (Fig. 36). We were able to detect mature neutrophils in 
healthy individual (Fig. 37a), CyN (Fig. 37b) and CN (Fig. 37c) derived iPSCs 
in our differentiation culture system, but the absolute cell numbers of mature 
neutrophils were markedly lower in the CN group, as compared to the healthy 
individual and CyN patient-derived iPSCs. 
 
 
 
 
 
 
 
Taken together, we found that using this protocol we can differentiate iPSCs 
into neutrophils from the healthy individual, CyN and CN patient-derived 
iPSCs, but not in the same quantity, as we described in Figure 34a. 
 
 
 
 
 
5 Discussion 
Figure 36. Wright-Giemsa–stained images of cytospin preparations from iPSCs-derived 
hematopoietic cells  
a, healthy individual in day 28 of culture b, CyN iPSCs in day 28 of culture c, CN iPSCs in day 28 of culture. 
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Use of ESCs and iPSCs will help us to improve our knowledge of the 
transcriptional networks on the lineage commitment and hematopoietic 
differentiation. Understanding of the new strategies for treatment of 
hematopoietic disorders and improvement of hematopoietic stem cell (HSC) 
transplantation needs more knowledge about stem cells and iPSCs has 
opened a promising field of therapeutic applications based on their efficient 
differentiation into hematopoietic cells.   
By imitating signaling pathways of the hematopoietic system, we have 
developed a stepwise  in vitro protocol for mouse ESCs and human iPSCs 
differentiation for the efficient generation of hematopoietic precursors and 
mature myeloid cells. 
Using this approach we have shown that hematopoietic differentiation of 
mouse-derived ES cells induced through a connection between the BMP4 
and TPO/c-mpl signaling pathway (Pramono, Zahabi et al. 2016). Treatment 
with TPO and enhancement of BMP4 target genes in ESCs and iPSCs may 
provide a new protocol for the generation of HSCs in clinical and experimental 
aspects.   
It has been shown that BMP4 will be regulated by sonic hedgehog (Shh) and 
effective concentrations of BMP4 for blood cell formation has been confirmed 
(Bhardwaj, Murdoch et al. 2001). VEGF provides autocrine support for the 
survival of HSCs in the early stages of hematopoiesis (Gerber, Malik et al. 
2002). It is also known that TPO can activate the VEGF production of ES cells 
during the first days of hematopoietic development (Kirito, Fox et al. 2005).  
The synergic contribution of VEGF and BMP4 to stimulate the formation of 
hematopoietic cells from differentiating ESC-derived EBs has been identified 
(Nakayama, Lee et al. 2000). Our data suggest that TPO/c-mpl signaling 
could initiate the production of BMP4 and enhancement of the hematopoietic 
differentiation of EC cells respectively (Pramono, Zahabi et al. 2016). 
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We have proposed a direct binding of HIF-1α as a transcription factor which 
is TPO-dependent to the BMP4 gene promoter for production of sufficient 
concentrations of BMP4 by undifferentiated ES cells for induction of 
hematopoietic cells (Fig.37) (Pramono, Zahabi et al. 2016).  
It is known that mesoderm formation and embryonic hematopoiesis induced 
under hypoxia condition; therefore HIF-1α is a crucial factor which is required 
for cell adaptation to low oxygen level conditions and it has an important role 
in primitive hematopoiesis (Huang and Bunn 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
We believe that using safe iPSCs generation methods and combination of 
synergic effects of hematopoietic cytokines with developmental regulators, 
Figure 37. Schema of TPO-dependent BMP4 regulation 
stabilization of HIF-1α protein by TPO and binding of HIF-1α to the BMP4 gene promoter could activate the 
autocrine synthesis of BMP4 and its target genes that results in in mouse ES cells derived early hematopoietic 
differentiation (Source from Pramono, Zahabi et al. 2016). 
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such as the morphogen BMP4, Wnt or Shh, we could provide useful methods 
for production of HSCs as a proper source of patient-specific cells. 
In the present study, we described the generation of iPSC lines of patients 
with CN and CyN. iPSCs have  several advantages in comparison to 
postnatal hematopoietic stem cells (Ye, Chou et al. 2012). iPSCs use allows 
the clonal expansion of cells with defined genetic signatures and their 
possible genetic modifications, which is difficult to perform in HSCs. Patient-
specific iPSCs are ideal sources for gene and cell therapy. We could use 
iPSCs of CN and CyN patients generated in this study for further drug 
screenings, in order to identify small molecules or other components capable 
of overcoming maturation arrest of granulopoiesis seen in CN patients. We 
could also use iPSCs of CN and CyN patients as an experimental model to 
study the mechanisms of leukemogenic transformation. 
The current challenges of the iPSCs technologies are the optimization of 
reprogramming methods for generation of safe iPSCs, and development of 
the efficient differentiation protocols for the generation of functional cell types 
(Ye, Chou et al. 2012).  
iPSCs are capable of differentiating into various lineages (Ebert, Yu et al. 
2009, Zhang, Wilson et al. 2009, Zahabi, Shahbazi et al. 2011) including 
endothelial and hematopoietic cell lineages (Choi, Yu et al. 2009, Lengerke, 
Grauer et al. 2009, Ye, Zhan et al. 2009, Feng, Lu et al. 2010, Slukvin, Choi 
et al. 2014). However, it is still challenging to differentiate the progenitor cells 
of the desired lineage with high efficiency and purity from iPSCs. 
There are two major approaches for hematopoietic differentiation of ESCs 
and iPSCs. One method involves co-culturing iPSCs with stromal cells such 
as murine OP9, C3H10T1/2, S17 or MS-5  as feeders (Wang, Au et al. 2007), 
(Kaufman, Hanson et al. 2001, Vodyanik, Bork et al. 2005, Miharada, 
Hiroyama et al. 2006). For the clinical applications and in order to prevent 
contamination with feeder cell products or antigen transmission, the second 
feeder-free culture system approach of iPSCs using embryoid body (EB) 
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formation would be more desirable (Pick, Azzola et al. 2007, Salvagiotto, 
Burton et al. 2011, Woods, Parker et al. 2011, Park, Zimmerlin et al. 2013). 
Efficient production of CD45+ hematopoietic cells from iPSCs has been 
reported by both culture methods using high-dose of hematopoietic growth 
factors (Ng, Davis et al. 2008, Nostro, Cheng et al. 2008, Pearson, 
Sroczynska et al. 2008). However, we still need to know how culture 
conditions and differentiation protocols affect lineage commitment. 
To establish the optimal conditions for hematopoietic differentiation of iPSCs, 
profound knowledge of the mechanisms operating during different distinct 
stages of differentiation are essential. The differentiation process in vitro into 
blood cells is divided into different stages with particular signals for 
mesodermal differentiation, hemato-endothelium, and hematopoietic stem 
cell- and progenitor cell specification, maturation, and expansion (Woods, 
Parker et al. 2011).  
ES cells can be enforced to differentiate into mesoderm and then into 
hematopoietic progenitors by specific cytokines. The most important 
cytokines at this stage are BMP4, a ventral mesoderm inducer (Chadwick, 
Wang et al. 2003), and VEGF (Nakayama, Lee et al. 2000, Park, Afrikanova 
et al. 2004). The critical  role of BMP4 in mesoderm formation and further 
hematopoietic differentiation in the posterior mesoderm has been identified 
in many species (Cerdan, McIntyre et al. 2012). We know that endothelial 
and hematopoietic cells can be formed from the mesoderm lineage in the 
extra-embryonic yolk sac following gastrulation (Cerdan, McIntyre et al. 
2012). 
It is also known that VEGF increases hemogenic endothelial cell proliferation 
and formation of hematopoietic cells. CD43 is the first marker, which is 
expressed in hematopoietic progenitors and which discriminate 
hematopoietic cells from endothelial cells during in vitro ES cells 
differentiation (Wang, Li et al. 2004). VEGF is identified as an inducer of 
CD31+ enriched hematoendothelial (HE) cells from early mesodermal cells  
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and commitment inducer of  HE cells into hematopoietic progenitors (Wang, 
Tang et al. 2012). 
In the present work, we established an efficient and directed differentiation 
method to generate neutrophils from human iPSCs using an EB based, 
feeder-free, serum-free, completely defined system. This protocol may be 
particularly suitable for studying human hematopoietic development and 
generating in vitro mature cells for cell and gene therapy. 
We designed an optimized 3-week protocol using serum free APEL medium, 
by step-wise addition of mesodermal induction cytokines (BMP4 and bFGF) 
to induce initial loss of pluripotency and appearance of the specification of 
myeloid CD11b+ cells. By further addition of hematopoietic growth factors 
(SCF, VEGF and IL-3), we induced differentiation of hematopoietic cells with 
production of approximately 40% of CD34+ hematopoietic cells and ca. 90 % 
of CD45+ cells on day 20 of culture.  
We also examined the myeloid differentiation potential of different 
hematopoietic cytokines, IL-3, GM-CSF and G-CSF in the conditions of our 
EB-based protocol of iPSCs differentiation. Interestingly, we achieved the 
best results using IL-3.  
In the context of adult hematopoiesis, IL-3 has been identified to support 
myelopoiesis, especially when used in combination with other growth factors 
such as G-CSF or GM-CSF (Krumwieh, Weinmann et al. 1990). More 
recently, IL-3 was also proven to elevate the development, proliferation and 
survival of early HSCs (Guzeloglu-Kayisli, Kayisli et al. 2009). 
 It has been reported that IL-3 is a supportive cytokine for the proliferation of 
a wide range of hematopoietic cells (Wiles and Keller 1991), while G-CSF 
and M-CSF are cytokines for specific myeloid differentiation. Appointed the 
emerging role of IL-3 in early primitive as well as definitive hematopoietic 
differentiation (Yang, Ciarletta et al. 1986), the fundamental importance of G-
CSF and M-CSF is rather in terminal granulocyte and monocyte/macrophage 
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differentiation (Clark and Kamen 1987, Welte, Bonilla et al. 1987, Sengupta, 
Liu et al. 1988). These observations may explain less potential effects of G-
CSF on the myeloid differentiation of iPSCs, as compared to IL-3. 
Interestingly, we observed that GM-CSF activity toward myeloid cells 
proliferation and maturation from iPSCs was similar to IL-3. It is known that 
IL-3 and GM-CSF exhibit similar effects in hematopoietic cells by usage of 
the same receptor ß-subunit. However, it is known that GM-CSF failed to 
induce granulopoiesis in CN patients. Even upon treatment with a high dose 
of GM-CSF we did not observe an elevation in neutrophil numbers in the 
peripheral blood of CN patients. G-CSF remains the only option for the 
treatment of CN patients.  
We have previously shown that G-CSF-triggered NAMPT expression and its 
product NAD+ in myeloid cells (Skokowa, Lan et al. 2009). NAMPT is a rate-
limiting enzyme which also known as a pre–B cell colony-enhancing factor 
(PBEF) (Zhang, Sang et al. 2010). Conversion of nicotinamide into NAD+ by 
NAMPT has been shown to be crucial for SIRT1 activation and granulocytic 
differentiation of CD34+ cells (Skokowa, Lan et al. 2009). Notably, vitamin B3 
as a substrate of NAMPT, led to neutrophilia after treatment of healthy 
individuals which shows a crucial role of NAMPT and NAD+ in myeloid 
differentiation (Skokowa, Lan et al. 2009). 
 Therefore, we sought to investigate the combined use of IL-3 with NAMPT 
or its substrate nicotinamide (NA) in our EB-based hematopoietic 
differentiation protocol of iPSCs. Our results showed that NAMPT or its 
substrate nicotinamide (NA) alone could not support properly in vitro myeloid 
cell proliferation and differentiation, while in the presence of IL-3, the number 
of floating hematopoietic and myeloid cells were dramatically increased. It 
would be interesting to study possible dose- and developmental stage- 
dependent effects of NAMPT and NA on the hematopoietic differentiation of 
iPSCs. Also, comparison of iPSCs from healthy individuals and from CN or 
CyN patients may be intriguing. 
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Using the EB-based protocol, we compared the potential of hiPSC lines 
generated from healthy individuals and from patients with CyN or CN to 
differentiate into hematopoietic progenitors and into mature myeloid cells. 
One of the strengths of generating patient-derived iPSCs is that the genetic 
signature of the patients is maintained. Thus, the described system will make 
it possible to differentiate CN and CyN iPSCs in parallel and compare the 
granulopoiesis as described above.  
Interestingly, we observed a logarithmic increase in generation of floating 
cells using iPSCs of the healthy individual and CyN patient. We observed the 
appearance of floating hematopoietic cells on day 14 of culture. Cell counts 
were continuously increased and reached a peak on day 30 of culture with 
subsequent decline until day 40- 45 where EBs stopped producing floating 
hematopoietic and myeloid cells. We found that myeloid differentiation of 
iPSCs derived from the CyN patient was comparable to that of the healthy 
individual derived iPSCs, as revealed by the analysis of the percentage and 
absolute numbers of CD45+CD11b+, CD45+CD16+ and CD45+CD15+ cells as 
well as by the examinations of the cell morphology on cytospin preparations. 
We could not detect any cycles of granulopoiesis using the EB-based 
protocol of differentiation of iPSCs derived CyN patients. Typically, peripheral 
blood neutrophil counts of CyN patients have approximately 21-day period 
cycles.  This could be explained by the fact that in our system we measured 
mixed cell populations produced simultaneously by different EBs.   
As expected, we found that iPSCs generated from the CN patient produced 
markedly reduced numbers of myeloid cells at early and late stages of 
differentiation, as compared to iPSCs generated from a healthy donor and 
from the CyN patient. Interestingly, although the absolute cell counts of iPSCs 
derived from the CN patient were much lower than in the other groups, 
morphological studies showed the presence of mature neutrophils in the CN 
group, which was comparable to CyN and healthy donor groups. Based on 
these observations, we were not able to recapitulate "maturation arrest" of 
granulopoiesis, seen in the bone marrow of CN patients before initiation of 
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G-CSF therapy. These observations may be explained by the experimental 
conditions used in our study. We used albumin-reach APEL medium and IL-
3/G-CSF stimulation. G-CSF is used for the life-long treatment of CN patients 
(Skokowa, Lan et al. 2009), however, daily injections of G-CSF doses 
between (100–1,000 times more than physiological levels) are needed for the 
enhancement of neutrophil counts in patients with CN disorders (Skokowa, 
Lan et al. 2009). Therefore, high-dose G-CSF is capable of differentiating 
HSCs of CN patients into granulocytes, but with very low efficiency. Our 
observations from in vitro EB-based differentiation of CN patient-derived 
iPSCs also confirmed the low efficiency of cytokine-triggered granulocytic 
differentiation.  
Taken together,  we observed reduced hematopoiesis in iPSCs derived from 
CN patients in this study as compared to healthy individual and CyN derived 
iPSCs. We found that although CN derived iPSCs could produce mature 
neutrophils, the potential for proliferation is very low compared to CyN and 
healthy individual derived iPSCs.  
Unaffected myeloid differentiation of iPSCs derived from the CyN patient 
could be explained by the fact that in CyN patients in vivo additional humoral 
or bone marrow niche components might influence myeloid cell cycling and 
additional modifier gene mutations or epigenetic defects in combination with 
mutated ELANE might be responsible for the pathogenesis of CyN. 
 
 
6 Outlook 
Reprogramming of somatic cells into pluripotent stem cells is a brilliant  
method that could be broadly used in the future for patient-specific stem cell-
based therapies. However, many issues remain to be solved before hiPSC-
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based therapy will enter the clinic. Virus-free reprogramming of somatic cells 
would be the most important issue in this direction.  
Safety of iPSCs is the main concern for iPSC-based therapy in clinical 
applications. Establishment of safe reprogramming methods to generate 
iPSCs and differentiation potential of iPSCs require further evaluation. 
Recent updates in iPSCs generation are: (1) reprogramming using the 
Sendai virus, (2) DNA-based episomal reprogramming, (3) induction of 
pluripotency via mRNA or protein expression.  
 Methods for large-scale production of mature cells of specific lineages from 
iPSCs in defined feeder-free conditions must be developed for translational 
studies. Understanding the disease pathogenesis and defining targets for the 
development of novel drugs for treatment or correcting defective signaling 
molecules is another challenging step.  
Gene modification and transplantation of HSCs demand the highest quality 
in iPSCs research  in  the  near future. Recent developments in gene targeting 
technologies such as CRISPR/Cas9 technologies have provided a valuable 
tool for research and for therapeutic applications of  iPSCs. 
In addition, usage of iPSCs for transplantation applications requires the quick 
cell preparations for universal purposes. Patient-specific iPSCs will prove to 
be useful for disease modeling In the near future. Moreover, unclear 
pathogenic mechanism based diseases or genetically induced disorders are 
obvious targets for patient-derived iPSCs therapeutic applications.  
In conclusion, the application of iPSCs to patients has the potential to provide 
a new light to clinical research. Indeed, safety limitations of using iPSCs must 
thoroughly be considered. Patient-specific iPSCs provide crucial new tools to 
improve our knowledge about disease pathogenesis and treatment 
strategies. Cell therapy with autologous patient-specific iPSCs is useful due 
to immune tolerance of autologous unlimited sources of the cells. These 
advantageous attributes should persuade further discoveries in the field of 
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iPSCs for translational research, disease modeling, and regenerative 
medicine, in both laboratory and clinical applications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
Das Ziel dieses Forschungsvorhabens ist es, die Mechanismen der 
hämatopoetischen Differenzierung, angefangen von sehr frühen Stadien bis zur 
myeloischen Differenzierung, zu untersuchen. Dafür haben wir die 
Differenzierung von murinen embryonalen Stammzellen (ES Zellen) Zellen sowie 
von humanen induzierten pluripotenten Stammzellen (iPS Zellen) verwendet. iPS 
Zellen sind re-programmierte somatische Zellen, die alle Merkmale embryonaler 
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Stammzellen tragen. Sie werden durch die Einführung der definierten 
Transkriptionsfaktoren (Oct 3/4, Sox2, Klf4, mit oder ohne c-MYC) in 
differenzierte somatische Zellen (e.g. Fibroblasten, CD34+ hämatopoetische 
Knochenmarkzellen, Keratinozyten) generiert. Die Untersuchungen an iPS Zellen 
können für das Verstehen der Prozesse der Lineage-Spezifizierung und 
Differenzierung von verschiedenen hämatopoetischen Reihen entscheidend 
sein. 
Im ersten Teil der Arbeit stellte sich heraus, dass ES-Zellen einen Rezeptor für 
Thrombopoetin (TPO), c-mpl exprimieren. Interessant ist, dass die Stimulation 
von ES Zellen mit TPO zusammen mit VEGF (Vascular Endothelial Growth 
Factor) die hämatopoetische Differenzierung dieser Zellen induziert. Es erfolgte 
durch Aktivierung von HIF1α (hypoxia-inducible factor-1 alpha) ein 
Transkriptionsfaktor, der an den Promoter des BMP4-Gens bindet und eine 
autokrine Sekretion von BMP4 bei diesen Zellen aktiviert. 
Im zweiten Teil der Arbeit haben wir ein Protokoll für die effiziente 
hämatopoetische Differenzierung von humanen iPS-Zellen etabliert. Wir haben 
auch die Effekte von IL-3, G-CSF, GM-CSF, NAMPT und Nikotinamide (NA) auf 
diese Differenzierung verglichen und haben festgestellt, dass die Kombination 
von IL-3 und G-CSF für unsere Zwecke am besten geeignet ist. Wir haben weiter 
die iPS Zellen von gesunden Spendern sowie von Patienten mit schwerer 
kongenitaler (CN) oder zyklischer (CyN) Neutropenie hergestellt und die 
myeloische Differenzierung dieser iPS Zellen verglichen. Wir haben entdeckt, 
dass die iPS-Zellen von CN-Patienten eine stark erniedrigte myeloische 
Differenzierung im Vergleich zu den iPS Zellen von CN-Patienten aufweisen. Im 
Gegensatz zeigten die iPS Zellen von CyN-Patienten nur eine leicht reduzierte 
myeloische Differenzierung. 
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